AKTX PE Ratio & Valuation,Is AKTX Overvalued

AKTX Relative Valuation

AKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKTX is overvalued; if below, it's undervalued.

Historical Valuation

Akari Therapeutics PLC (AKTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 104.95. The fair price of Akari Therapeutics PLC (AKTX) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：0.41

Fair

-0.80

0.00

EV/EBITDA

Akari Therapeutics PLC. (AKTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.97

EV/EBIT

Akari Therapeutics PLC. (AKTX) has a current EV/EBIT of -0.97. The 5-year average EV/EBIT is -1.64. The thresholds are as follows: Strongly Undervalued below -4.07, Undervalued between -4.07 and -2.86, Fairly Valued between -0.43 and -2.86, Overvalued between -0.43 and 0.78, and Strongly Overvalued above 0.78. The current Forward EV/EBIT of -0.97 falls within the Historic Trend Line -Fairly Valued range.

0.00

Akari Therapeutics PLC. (AKTX) has a current PS of 0.00. The 5-year average PS is 0.39. The thresholds are as follows: Strongly Undervalued below -3.43, Undervalued between -3.43 and -1.52, Fairly Valued between 2.29 and -1.52, Overvalued between 2.29 and 4.20, and Strongly Overvalued above 4.20. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.84

P/OCF

Akari Therapeutics PLC. (AKTX) has a current P/OCF of -0.84. The 5-year average P/OCF is -1.86. The thresholds are as follows: Strongly Undervalued below -4.68, Undervalued between -4.68 and -3.27, Fairly Valued between -0.45 and -3.27, Overvalued between -0.45 and 0.97, and Strongly Overvalued above 0.97. The current Forward P/OCF of -0.84 falls within the Historic Trend Line -Fairly Valued range.

-0.75

P/FCF

Akari Therapeutics PLC. (AKTX) has a current P/FCF of -0.75. The 5-year average P/FCF is -1.80. The thresholds are as follows: Strongly Undervalued below -5.60, Undervalued between -5.60 and -3.70, Fairly Valued between 0.10 and -3.70, Overvalued between 0.10 and 2.00, and Strongly Overvalued above 2.00. The current Forward P/FCF of -0.75 falls within the Historic Trend Line -Fairly Valued range.

Akari Therapeutics PLC (AKTX) has a current Price-to-Book (P/B) ratio of 0.58. Compared to its 3-year average P/B ratio of -12.41 , the current P/B ratio is approximately -104.64% higher. Relative to its 5-year average P/B ratio of -1.09, the current P/B ratio is about -152.75% higher. Akari Therapeutics PLC (AKTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -71.16%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -53.91% , the current FCF yield is about -100.00% lower.

0.58

P/B

Median3y

-12.41

Median5y

-1.09

-69.35

FCF Yield

Median3y

-71.16

Median5y

-53.91

Competitors Valuation Multiple

The average P/S ratio for AKTX's competitors is 0.00, providing a benchmark for relative valuation. Akari Therapeutics PLC Corp (AKTX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of AKTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of AKTX in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Akari Therapeutics PLC (AKTX) currently overvalued or undervalued?

What is Akari Therapeutics PLC (AKTX) fair value?

AKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Akari Therapeutics PLC (AKTX) is between to according to relative valuation methord.

How does AKTX's valuation metrics compare to the industry average?

What is the current P/B ratio for Akari Therapeutics PLC (AKTX) as of Dec 16 2025?

As of Dec 16 2025, Akari Therapeutics PLC (AKTX) has a P/B ratio of 0.58. This indicates that the market values AKTX at 0.58 times its book value.

What is the current FCF Yield for Akari Therapeutics PLC (AKTX) as of Dec 16 2025?

As of Dec 16 2025, Akari Therapeutics PLC (AKTX) has a FCF Yield of 0.00%. This means that for every dollar of Akari Therapeutics PLC’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Akari Therapeutics PLC (AKTX) as of Dec 16 2025?

As of Dec 16 2025, Akari Therapeutics PLC (AKTX) has a Forward P/E ratio of -0.80. This means the market is willing to pay $-0.80 for every dollar of Akari Therapeutics PLC’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Akari Therapeutics PLC (AKTX) as of Dec 16 2025?

As of Dec 16 2025, Akari Therapeutics PLC (AKTX) has a Forward P/S ratio of 0.00. This means the market is valuing AKTX at $0.00 for every dollar of expected revenue over the next 12 months.

AKTX Valuation